Insider buying last 90 days
No open-market insider purchases were filed for BLTE in the last 90 days.
From Form 4 filings, dated to when each was filed.
Belite Bio closed at $157.69 on 9 November 2026, +2.3% on the day. The price sits between the 50-day ($160.83) and 200-day ($160.20) moving averages, inside a 52-week range of $102.00 to $200.00. The GekkoIndex reads 57.3, in the Neutral zone, down 2.7 points over five sessions. Gekko Fair Value is $172.40, so the price is 8.5% below it.
The next earnings report is due on 12 November 2026, 106 days away. Over the last 8 reports the company beat the earnings estimate 2 times, with an average move of 5% across the report. Seasonally, the next 20 trading days from this point averaged +8.7% over the last 4 years, rising in 3 of them.
7 firms rate the stock: 7 buy, 0 hold and 0 sell, with a consensus target of $227.44. A typical daily move is about 4.3%, and a typical 20-day move about 10.1%. On the swing-trade checklist, 2 items read supportive and 1 reads as a headwind (earnings risk).
A plain summary of the figures as of the Nov 9, 2026 close.
Belite Bio scores 4 supportive, 1 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed0 headwinds
Above 50 and 200-day
Close $164.36 is above the 50-day ($160.88) and 200-day ($160.11) averages, and the 50-day is above the 200-day.
See the chart52.2, Neutral
Reading 52.2 is in the Neutral zone.
See the GekkoIndex5.8% below
Price is 5.8% below Gekko Fair Value (more than 5% below).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 106 days
Next report Mar 1, 2027, 106 days away — outside a typical 20-trading-day hold.
See earnings+8.1% on average
From this point in the calendar, the next 20 trading days averaged +8.1% over 4 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Belite Bio closed at $164.36 on Nov 13, 2026, +48.3% over the past year, inside a 52-week range of $105.88 to $200.00.
Use the left and right arrow keys to read daily values.
Put BLTE on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Belite Bio is a clinical-stage biopharmaceutical company that works on developing treatments still in the testing stages, rather than products already on the market. Much of its research centers on eye disorders, particularly atrophic age-related macular degeneration and a form of Stargardt disease that runs in families. Its best-known program is LBS-008, an oral drug taken once a day that is now in Phase 3 trials and is meant to control how vitamin A moves to the eye, limiting the buildup of certain vitamin A byproducts that can damage eye tissue.
The company also has a second program, LBS-009, which is being studied in earlier, preclinical stages. This candidate works by blocking retinol binding protein 4 and is intended for liver-related conditions such as fatty liver disease, steatohepatitis, and type 2 diabetes. Belite Bio functions as part of Lin Bioscience International Ltd.
Belite Bio was started in 2016 and has its main offices in San Diego, California. Its stock trades under the ticker BLTE.
Belite Bio’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 52.2, in the Neutral zone, down 7.9 points over five sessions.
Down 7.9 points over five sessions, from the Accumulation zone.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 25 | +2.7% | +3.6% | ||
| Accumulation | 182 | +1.0% | +5.0% | ||
| Neutral (current zone) | 355 | +1.2% | +4.8% | ||
| Distribution | 87 | +1.1% | +7.9% | ||
| Selling | 6 | Too few readings yet | |||
Average BLTE share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Belite Bio trades 5.8% below Gekko Fair Value of $174.40, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Belite Bio shares are worth, recalculated every trading day.
$174.40
Gekko Fair Value, Nov 14, 2026
5.8% Undervalued
At the end of Aug 2026 the price was 21.7% below the estimate.
No open-market insider purchases were filed for Belite Bio, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for BLTE in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in BLTE were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
1of the funds Gekko tracks holds BLTE.
Belite Bio reports on Mar 1, 2027 (106 days away), and beat the EPS estimate in 3 of its last 8 reports.
Mar 1, 2027
106 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Nov 12, 2026 | −$0.60 est −$0.79 | — | +5.4% |
| Aug 12, 2026 | −$0.70 est −$0.73 | — | −6.4% |
| May 20, 2026 | −$0.68 est −$0.64 | — est $16.67M | +3.3% |
| Mar 2, 2026 | −$0.70 est −$0.54 | — est $16.67M | −11.8% |
| Nov 10, 2025 | −$0.65 est −$0.49 | — | −6.6% |
| Aug 11, 2025 | −$0.50 est −$0.47 | — | +4.1% |
| May 13, 2025 | −$0.45 est −$0.36 | — | −0.6% |
| Nov 12, 2024 | −$0.28 est −$0.29 | — | +4.6% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Belite Bio is $230.78, +40.4% from the last close, from 5 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 5 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 13 | Leerink Partners | $215 | +30.8% |
| Nov 13 | H.C. Wainwright | $245 | +49.1% |
| Oct 15 | H.C. Wainwright | $245 | +49.1% |
| Sep 9 | Mizuho Securities | $234 | +42.4% |
| Sep 9 | H.C. Wainwright | $245 | +49.1% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Belite Bio averaged +8.1% across the last 4 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +4.9% | 3 of 4 |
| Next 10 trading days | +10.6% | 3 of 4 |
| Next 15 trading days | +10.6% | 3 of 4 |
| Next 20 trading days | +8.1% | 3 of 4 |
| Next 30 trading days | +12.6% | 3 of 4 |
For scale, BLTE’s typical 20-trading-day move in either direction is about 10.1%.
Belite Bio’s market cap is $6.62B and revenue of $0 over the last twelve months.
Coverage of Belite Bio this week reads positive: 5 positive, 2 neutral and 1 negative headlines.
Belite Bio’s market cap is $6.62B at the Nov 13, 2026 close of $164.36, with 40.27M shares outstanding.
The consensus analyst 12-month price target for Belite Bio is $230.78, +40.4% from the last close. Of the 5 firms that rated the stock in the last 90 days, 5 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Belite Bio is undervalued: the Nov 13, 2026 close of $164.36 is 5.8% below Gekko Fair Value of $174.40. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Belite Bio is expected to report on Mar 1, 2027 (106 days away). Analysts expect earnings of −$0.79 per share on revenue of $25.71M. Belite Bio beat the earnings estimate in 3 of its last 8 reports, moving 5.4% on average across the report.
Belite Bio’s 52-week high is $200.00 and its 52-week low is $105.88; it closed at $164.36 on Nov 13, 2026, +48.3% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 5 items with data read as supportive (trend, fair value, earnings risk and seasonality), 1 as mixed (gekkoindex). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.